COMMUNIQUÉS West-GlobeNewswire

Nexstim Receives Order for NBS System 5 in Finland
27/09/2024
Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for an NBS System [...]
Information on the total number of voting rights and shares
27/09/2024
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), September 27, 2024 , 08:05 am CET / 2:05 am ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
26/09/2024
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April [...]
Cue Biopharma Announces Proposed Public Offering
26/09/2024
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health
26/09/2024
Sustained Sales Momentum in China in Q3 Following 37% Sequential Growth in Q2 Acquisition of SRx Health Remains On-Track TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice [...]
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
26/09/2024
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, [...]
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
26/09/2024
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine [...]
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
26/09/2024
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term milestones WARRINGTON, [...]
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
26/09/2024
Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s [...]
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
26/09/2024
TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based [...]
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
26/09/2024
Company to host conference call today at 4:30 p.m. ET SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study [...]
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
26/09/2024
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve [...]
Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations
26/09/2024
New Jersey Native Joseph Brand to Lead Operational Efficiency and Innovation in MA Operations, Enhancing Care for Physicians and Patients FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26/09/2024
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and [...]
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
26/09/2024
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent [...]
Corza Medical remporte le Prix d’excellence mondial 2024 du fabricant de solutions de suture de plaies le plus innovant
26/09/2024
WESTWOOD, Massachusetts, 26 sept. 2024 (GLOBE NEWSWIRE) -- Corza Medical (« Corza » ou la « Société »), une entreprise de technologie médicale de premier rang à l’échelle mondiale, proposant des services remarquables, [...]
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
26/09/2024
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow [...]
Culture Biosciences Appoints Chris Williams as Chief Executive Officer
26/09/2024
Former COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences South San Francisco, CA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in [...]
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
26/09/2024
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new partnerships. New strategic [...]

Pages